Piotr Waciński

Prof. Piotr Waciński

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2011 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
MHMarek Hus
Marek Hus
NGNorbert Grząśko
Norbert Grząśko
MSMarta Szostek
Marta Szostek
APAndrzej Pluta
Andrzej Pluta
GHGrzegorz Helbig
Grzegorz Helbig
ADAnna Dmoszynska
Anna Dmoszynska
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib. Lovastatin and other inhibitors of HMG-CoA reductase demonstrated to exhibit antineoplasmatic and proapoptotic properties in numerous in vitro studies involving myeloma cell lines. We treated 91 patients with relapsed or refractory multiple myeloma with thalidomide, dexamethasone and lovastatin (TDL group, 49 patients) or thalidomide and dexamethasone (TD group, 42 patients). A clinical response defined of at least 50% reduction of monoclonal band has been observed in 32% of TD patients and 44% of TDL patients. Prolongation of overall survival and progression-free survival in the TDL group as compared with the TD group has been documented. The TDL regimen was safe and well tolerated. The incidence of side effects was comparable in both groups. Plasma cells have been cultured in vitro with thalidomide and lovastatin to assess the impact of both drugs on the apoptosis rate of plasma cells. In vitro experiments revealed that the combination of thalidomide and lovastatin induced higher apoptosis rate than apoptosis induced by each drug alone. Our results suggest that the addition of lovastatin to the TD regimen may improve the response rate in patients with relapsed or refractory myeloma.

1 September 2014 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
PZPawel Zukowski
Pawel Zukowski
PWPiotr Waciński
Piotr Waciński
KKKatarzyna Ksiazek
Katarzyna Ksiazek
WZWojciech Zaluska
Wojciech Zaluska

1 June 2016 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
PZPawel Zukowski
Pawel Zukowski
KKKatarzyna Ksiazek
Katarzyna Ksiazek
PWPiotr Waciński
Piotr Waciński
MDMichal Dragan
Michal Dragan

2 May 2019 in Immunological Investigations
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
KKKatarzyna Ksiazek
Katarzyna Ksiazek
PWPiotr Waciński
Piotr Waciński
WZWojciech Zaluska
Wojciech Zaluska
Objective: Cytokines play an important role in the pathogenesis of type 2 diabetes (T2DM) and its complications. The aim of the study was to evaluate an association of the −511 (C/T) polymorphism in the IL1B gene with diabetic nephropathy (DN). Methods: The study population included 860 patients with T2DM (506 with diabetic nephropathy and 354 without nephropathy) as well as 505 healthy individuals. Genomic DNA was genotyped for the IL1B −511 (C/T) polymorphism using PCR-RFLP technique. Results: The IL1B −511 C/T polymorphism was genotyped in 860 T2DM patients with or without DN and 505 healthy individuals. The average age of patients was 65.3 years in DN+ and 62.2 years in DN- subgroups. The genotype distribution did not differ significantly between patients and controls. Only a tendency to a slight increase of T allele frequency was observed in patient group. Genotype and allele frequencies of −511 C/T polymorphism were compared in patients with DN and those without it. The minor allele (T) and homozygote TT frequencies were significantly different between subgroups. The T allele was more frequent in DN+ patients, with odds ratio 1.45 (95% CI 1.2–1.8), p = 0.0003. The TT genotype frequency was also higher in DN+, with OR 1.76 (96% CI 1.1–2.7), p = 0.01. Conclusion: In a studied population the −511 C/T polymorphism in the IL1B gene is associated with diabetic nephropathy in dialyzed T2DM patients. Further studies are required to confirm the clinical significance of this finding.

1 January 2014 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
PWPiotr Waciński
Piotr Waciński
PZPawel Zukowski
Pawel Zukowski
MDMichal Dragan
Michal Dragan
AKAndrzej Ksiazek
Andrzej Ksiazek

1 June 2012 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
WDWojciech Dabrowski
Wojciech Dabrowski
ZRZiemowit Rzecki
Ziemowit Rzecki
MCMarek Czajkowski
Marek Czajkowski
JPJacek Pilat
Jacek Pilat
PWPiotr Waciński
Piotr Waciński
KPKazimierz Pasternak
Kazimierz Pasternak